John S. Abrams, PhD, discusses some of the cutting-edge work he’s involved in and what he’s looking forward to at this year's Emerald Conference.
As the Emerald Conference quickly approaches, we spoke with John S. Abrams, PhD-Principal of Abrams Bioconsulting, Chairman and CSO of The CESC, and CSO of Orion GMP Solutions-to get some insider information on the type of science we can expect to hear at this year’s conference. Here, Abrams discusses some of the cutting-edge work he’s involved in and what he’s looking forward to at the conference.
How is the industry establishing regulations and compliance in a scientifically sound and evidence-based manner?
John S. Abrams: Establishing regulations and compliance in a scientifically sound and evidence-based manner is a slow and evolving process. It doesn't happen quickly, and sometimes it is not straightforward. As we emerge from the shadows of prohibition, we have to be mindful of not having to reinvent the wheel each time.
We should look to other industries where there are relevant, useful, and validated approaches. There are, however, some approaches which come from the early days of back-alley cannabis labs that need to be scrutinized and re-evaluated in the light of good scientific practices. This is particularly relevant in the context of designing sampling plans. Additionally, analysts in this field need to realize that their methods should be open, discussed, and reviewed. This is neither the time nor the place to be considering analytical approaches as proprietary-we must collaborate.
Finally, I would like to add that the industry should collectively support federal descheduling as quickly as possible to allow interstate transport of samples for analytical purposes. That way, the best and most advanced analytical facilities can help establish answers to the more difficult questions in cannabis science.
What is the significance of multivariate statistics and design of experiments (DOE) in cannabis strain chemotype profiling?
Abrams: Cannabis is a complex botanical. It contains a myriad of natural products. In some combinations they confer the desirable properties of the cannabis commodity. Statistical approaches like multivariate analysis can be useful for simplifying that complexity. The goal of multivariate analysis is to come up with a limited set of parameters, of answers to communicating the complexity of cannabis natural product content that product users can more easily understand, and to tie their experience to approaches such as design of experiments (DOE), provide a framework for cultivators trying to understand what key factors may affect cannabinoid and terpenoid production. These are the key elements defining cannabis chemotypes.
DOE allows for simplification and reduction in the number of different experimental runs required to draw meaningful conclusions. It is fundamentally a way to get more bang for your research buck.
How has applying antibody development and immunoassay-based technologies advanced cannabis product assays?
Abrams: Like so much in the cannabis science field, applying antibody development and immunoassay-based technologies to advance cannabis product assays is a developing story. We are actively pursuing the development of in-vitro cell-based bioassays to determine functional activity (what we really mean when we say "potency") of various cannabinoids such as THCA and CBDA. We rely on antibodies as tools to provide specificity and selectivity to such cannabinoid bioassays. This is one of the principal reasons I developed such anti-CBD(A) antibodies several years ago.
As a scientific committee member of the Emerald Conference, what do you look forward to most at the conference?
Abrams: As a scientific committee member of the Emerald Conference, what I’m looking forward to most at this year’s conference is the opportunity to foster collaboration and innovation with like-minded participants.
There are many different ways to become informed on cutting edge knowledge and state-of-the-art innovation including:
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.